Filip Janku

CIK: 0001862930

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (45.5%)

Position reduction

Option Exercises (M)3 (27.3%)

Derivative conversions

Awards (A)3 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GLUE

Monte Rosa Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

GLUE
Monte Rosa Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
5.4K shares at avg. $24.50$132K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 30, 2026
Exercise(M)
Direct
5.4K shares at avg. $13.41$73K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 24, 2026
Exercise(M)
Direct
30K shares at avg. $7.56$227K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 24, 2026
Sale(S)
Direct
30K shares at avg. $21.42$643K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 23, 2026
Exercise(M)
Direct
6K shares at avg. $7.56$45K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 23, 2026
Sale(S)
Direct
11.8K shares at avg. $20.22$240K
GLUE
Monte Rosa Therapeutics, Inc.
Feb 23, 2026
Sale(S)
Direct
9.2K shares at avg. $19.50$179K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
3.2K shares at avg. $15.17$48K
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
31K shares-
GLUE
Monte Rosa Therapeutics, Inc.
Jan 2, 2025
Award(A)
Direct
36K shares-
GLUE
Monte Rosa Therapeutics, Inc.
Sep 13, 2024
Award(A)
Stock Option (Right to Buy)
Direct
30K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	5,407	$24.50	$132,472	Direct
Jun 30, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	5,407	$13.41	$72,508	Direct
Jun 24, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	30,000	$7.56	$226,800	Direct
Jun 24, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	30,000	$21.42	$642,681	Direct
Jun 23, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	6,000	$7.56	$45,360	Direct
Jun 23, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	11,845	$20.22	$239,522	Direct
Feb 23, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	9,189	$19.50	$179,161	Direct
Jan 5, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	3,155	$15.17	$47,861	Direct
Jan 2, 2026	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	31,000	-	$0	Direct
Jan 2, 2025	GLUE Monte Rosa Therapeutics, Inc.	Award(A)	36,000	-	$0	Direct
Sep 13, 2024	GLUE Monte Rosa Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	30,000	-	-	Direct

1-11 of 11 transactions

About Janku Filip

Janku Filip (SEC CIK 0001862930) files insider reports with the SEC as Chief Medical Officer of Monte Rosa Therapeutics, Inc. (GLUE).

Signal8 holds 6 ownership filings by Janku Filip, all Form 4s, filed between Sep 13, 2024 and Jul 1, 2026. Those filings report 11 transactions, from Sep 13, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Janku Filip's filings is in BOSTON, MA.

Recent filings by Janku Filip

Jun 30, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jun 30, 2026: Option exercise of GLUE shares (Form 4, code M).
Jun 24, 2026: Option exercise of GLUE shares (Form 4, code M).
Jun 24, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jun 23, 2026: Option exercise of GLUE shares (Form 4, code M).

Other insiders filing for Monte Rosa Therapeutics, Inc. (GLUE)

Bowen Matthew, Principal Accounting Officer
Warmuth Markus, President & CEO
Champoux Jennifer, Chief Operating Officer
Townson Sharon, Chief Scientific Officer
Behbahani Ali, Director
SCHIFF ANDREW N, Director

How to read Form 4 transaction codes